A Phase 3 interventional study of Letermovir in Cytomegalovirus Infections, Kidney Transplant Infection and Pancreas Transplant, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by University of Wisconsin, Madison · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing letermovir in Cytomegalovirus Infections — 7 open to participants now, 8 under way, 3 of them phase 3. letermovir · Cytomegalovirus Infections.
Among the 17 studies testing letermovir in Cytomegalovirus Infections, this one is the 6th largest by planned enrollment, is one of 5 that started in 2024, is one of 6 in phase 3, and was the 15th registered.
370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.
Browse Cytomegalovirus Infections studies →7 of the 17 studies testing letermovir in Cytomegalovirus Infections are open now, in 4 countries. Recruiting first, the newest first:
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Elisabeth Kincaide · Sites in United States
Ages 18+
Hospital do Rim e Hipertensão
Ages 18+
Maimónides Biomedical Research Institute of Córdoba · Sites in Spain
Ages 18+
By country, each count listing its studies:
letermovir: first FDA approval 2017 (PREVYMIS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 5 started in 2024.
This study's planned enrollment of 90 is above the median of 64 across 240 interventional studies indexed under Cytomegalovirus Infections.
Median enrollment 80 across the 17 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 17 have an industry lead sponsor. The 10 most frequent:
University of Wisconsin, Madison is the lead sponsor of 1,190 studies on the registry; 181 are open to participants now.
Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.
University of Wisconsin, Madison has 3 studies filed under Cytomegalovirus Infections — fewer than ten, so there is no comparison to draw.
4 of the studies testing letermovir in Cytomegalovirus Infections that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06407232Phase 3University of Wisconsin, MadisonLetermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients | 2027-08 |
| NCT06334497Phase 3Assistance Publique - Hôpitaux de ParisLetermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections | 2027-09 |
| NCT06066957University of PennsylvaniaOpen Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients | 2026-12-15 |
| NCT06057194Maimónides Biomedical Research Institute of CórdobaEfficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir. | 2027-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies testing letermovir in Cytomegalovirus Infections, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.
Study Population: Patients over 18 years of age who have undergone kidney or simultaneous kidney/pancreas transplant and are high-risk CMV serostatus (D+/R-) at time of transplant who develop CMV viremia that necessitates treatment per our institutional protocol (enrolled in our CMV stewardship monitoring initiative) and demonstrate proven or presumptive lack of cell-mediated immunity, either by CMI testing or risk factor screening.
Patients will be converted from treatment with ganciclovir derivatives to letermovir (480 mg tablet taken orally once daily) when the viral load via standard of care (SOC) weekly monitoring is \< 500 IU/mL. This differs from SOC which only allows conversion to secondary prophylactic treatment after CMV is no longer detected on polymerase chain reaction (PCR) for 2 consecutive weeks. Thus, liberalization of conversion threshold will allow for reduced exposure to valganciclovir via reduced duration of therapy allowing relief of the myelosuppressive toxicity and creates an environment conducive to cell-mediated immunity (CMI).
The primary objective is to assess the efficacy of letermovir as secondary prophylaxis after treatment of CMV infection.
The secondary objective is to detect the development of cytomegalovirus-specific cell-mediated immunity as determined by a positive result using the Eurofins-Viracor CMV inSIGHTTM T Cell Immunity Testing per manufacturer specifications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Enrolled participants will be converted from treatment with ganciclovir derivatives to letermovir
Drug: Letermovir
480 mg taken orally once daily, for 84 days
Also known as: Prevymis
Number of distinct episodes of any cytomegalovirus replication greater than 1000 IU/mL
To test the hypothesis that letermovir will be associated with reduced incidence of recurrent viremia, recurrence will be measured defined as incidence of any cytomegalovirus replication greater than 1000 IU/mL requiring treatment after withdrawal of secondary prophylaxis.
Time frame: up to 90 days after withdrawal of secondary prophylaxis (up to 6 months on study)
Duration of valganciclovir (VGC) Treatment
To test the hypothesis that letermovir will be associated with reduced duration of (val)ganciclovir treatment, the duration of VGC treatment will be measured.
Time frame: up to 2 months
Number of Participants with Positive Result for T-Cell Immunity Panel (TCIP) Testing
To test the hypothesis that letermovir will be associated with increased development of cytomegalovirus-specific cell-mediated immunity when compared to a literature-based control, development of cytomegalovirus-specific cell-mediated immunity as determined by a positive result using the Eurofins-Viracor CMV inSIGHTTM T-Cell Immunity Testing per manufacturer specifications will be measured. TCIP will be collected from the medical record at these timepoints if possible. Given SOC, access to this test is not always available to all patients at both timepoints.
Time frame: letermovir initiation (Day 0), at secondary prophylaxis completion (Week 12 +/- 28 days)
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Aug 2027, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Letermovir
University of Wisconsin, Madison →